BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26041837)

  • 21. The potential pathway of FOXC1 high expression in regulating the proliferation, migration, cell cycle and epithelialmesenchymal transition of basal-like breast cancer and in vivo imaging.
    Zuo H; Yang Q
    J BUON; 2018; 23(3):720-728. PubMed ID: 30003742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-cadherin and vimentin are useful basal markers in breast cancers.
    Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
    Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
    Asleh-Aburaya K; Sheffield BS; Kos Z; Won JR; Wang XQ; Gao D; Wolber R; Gilks CB; Bernard PS; Chia SK; Nielsen TO
    Histopathology; 2017 Jan; 70(2):185-194. PubMed ID: 27402148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low expression of PinX1 is associated with malignant behavior in basal-like breast cancer.
    Feng YZ; Zhang QY; Fu MT; Zhang ZF; Wei M; Zhou JY; Shi R
    Oncol Rep; 2017 Jul; 38(1):109-119. PubMed ID: 28586040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues.
    Mullins M; Perreard L; Quackenbush JF; Gauthier N; Bayer S; Ellis M; Parker J; Perou CM; Szabo A; Bernard PS
    Clin Chem; 2007 Jul; 53(7):1273-9. PubMed ID: 17525107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression level of miR-93 in formalin-fixed paraffin-embedded tissues of breast cancer patients.
    Deng ZQ; Qian J; Liu FQ; Lin J; Shao R; Yin JY; Tang Q; Zhang M; He L
    Genet Test Mol Biomarkers; 2014 May; 18(5):366-70. PubMed ID: 24606013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.
    Annaratone L; Simonetti M; Wernersson E; Marchiò C; Garnerone S; Scalzo MS; Bienko M; Chiarle R; Sapino A; Crosetto N
    Oncotarget; 2017 Mar; 8(12):18680-18698. PubMed ID: 28423635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
    Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
    Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
    J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene-expression analysis of a colorectal cancer-specific discriminatory transcript set on formalin-fixed, paraffin-embedded (FFPE) tissue samples.
    Kalmár A; Wichmann B; Galamb O; Spisák S; Tóth K; Leiszter K; Nielsen BS; Barták BK; Tulassay Z; Molnár B
    Diagn Pathol; 2015 Jul; 10():126. PubMed ID: 26208990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
    Yamamoto S; Ibusuki M; Yamamoto Y; Fu P; Fujiwara S; Murakami K; Iwase H
    Breast Cancer; 2013 Jul; 20(3):262-70. PubMed ID: 22362219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Divisional role of quantitative HER2 testing in breast cancer.
    Yamamoto-Ibusuki M; Yamamoto Y; Fu P; Yamamoto S; Fujiwara S; Honda Y; Iyama K; Iwase H
    Breast Cancer; 2015 Mar; 22(2):161-71. PubMed ID: 23604955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXC1.
    Li M; Lv H; Zhong S; Zhou S; Lu H; Yang W
    Arch Pathol Lab Med; 2022 Aug; 146(8):994-1003. PubMed ID: 34784418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer.
    Liu T; Zhang X; Shang M; Zhang Y; Xia B; Niu M; Liu Y; Pang D
    J Surg Oncol; 2013 Feb; 107(2):188-94. PubMed ID: 22886823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer.
    Han B; Qu Y; Jin Y; Yu Y; Deng N; Wawrowsky K; Zhang X; Li N; Bose S; Wang Q; Sakkiah S; Abrol R; Jensen TW; Berman BP; Tanaka H; Johnson J; Gao B; Hao J; Liu Z; Buttyan R; Ray PS; Hung MC; Giuliano AE; Cui X
    Cell Rep; 2015 Nov; 13(5):1046-58. PubMed ID: 26565916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Forkhead box C1 promoter upstream transcript, a novel long non-coding RNA, regulates proliferation and migration in basal-like breast cancer.
    Liu J; Shen L; Yao J; Li Y; Wang Y; Chen H; Geng P
    Mol Med Rep; 2015 Apr; 11(4):3155-9. PubMed ID: 25516208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
    Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
    J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
    Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
    Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.